Cargando…
PET/CT imaging detects intestinal inflammation in a mouse model of doxorubicin-induced mucositis
INTRODUCTION: A severe side effect of cancer chemotherapy is the development of gastrointestinal mucositis, characterised by mucosal inflammation. We investigated if 2-deoxy-2-[(18)F] fluoro-D-glucose positron emission tomography combined with computed tomography (2-[(18)F]FDG-PET/CT) could visualis...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798215/ https://www.ncbi.nlm.nih.gov/pubmed/36591502 http://dx.doi.org/10.3389/fonc.2022.1061804 |
_version_ | 1784860860199469056 |
---|---|
author | Dalby, Sina Skallerup, Sofie Baun, Christina Christensen, Lene Gaarsmand Rathe, Mathias Palner, Mikael Husby, Steffen Moeller, Jesper Bonnet |
author_facet | Dalby, Sina Skallerup, Sofie Baun, Christina Christensen, Lene Gaarsmand Rathe, Mathias Palner, Mikael Husby, Steffen Moeller, Jesper Bonnet |
author_sort | Dalby, Sina |
collection | PubMed |
description | INTRODUCTION: A severe side effect of cancer chemotherapy is the development of gastrointestinal mucositis, characterised by mucosal inflammation. We investigated if 2-deoxy-2-[(18)F] fluoro-D-glucose positron emission tomography combined with computed tomography (2-[(18)F]FDG-PET/CT) could visualise gastrointestinal mucositis in mice treated with the chemotherapeutic agent doxorubicin. METHODS: In this study, gastrointestinal inflammation was longitudinally evaluated by 2-[(18)F]FDG-PET/CT scans before and 1, 3, 6, and 10 days after treatment with doxorubicin. Doxorubicin-treated mice were compared to saline-treated littermates using the abdominal standard uptake value of 2-[(18)F]FDG corrected for body weight (SUV(BW)). RESULTS: Abdominal SUV(BW) was significantly increased on day 1 (p < 0.0001), day 3 (p < 0.0001), and day 6 (p < 0.05) in the doxorubicin-treated group compared to controls. Abdominal SUV(BW) returned to baseline levels on day 10. In the doxorubicin group, the largest weight loss was observed on day 3 (control vs doxorubicin, mean percent of baseline weight: (98.5 ± 3.2% vs 87.9 ± 4.6%, p < 0.0001). Moreover, in the doxorubicin-treated group, villus lengths were decreased by 23-28% on days 1 and 3 in the small intestine (p < 0.05), and jejunal levels of tumour necrosis factor and interleukin-1β were significantly increased on day 3 (p < 0.05). DISCUSSION: Together, these findings indicate that sequential 2-[(18)F]FDG-PET/CT scans can objectively quantify and evaluate the development and resolution of intestinal inflammation over time in a mouse model of doxorubicin-induced mucositis. |
format | Online Article Text |
id | pubmed-9798215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97982152022-12-30 PET/CT imaging detects intestinal inflammation in a mouse model of doxorubicin-induced mucositis Dalby, Sina Skallerup, Sofie Baun, Christina Christensen, Lene Gaarsmand Rathe, Mathias Palner, Mikael Husby, Steffen Moeller, Jesper Bonnet Front Oncol Oncology INTRODUCTION: A severe side effect of cancer chemotherapy is the development of gastrointestinal mucositis, characterised by mucosal inflammation. We investigated if 2-deoxy-2-[(18)F] fluoro-D-glucose positron emission tomography combined with computed tomography (2-[(18)F]FDG-PET/CT) could visualise gastrointestinal mucositis in mice treated with the chemotherapeutic agent doxorubicin. METHODS: In this study, gastrointestinal inflammation was longitudinally evaluated by 2-[(18)F]FDG-PET/CT scans before and 1, 3, 6, and 10 days after treatment with doxorubicin. Doxorubicin-treated mice were compared to saline-treated littermates using the abdominal standard uptake value of 2-[(18)F]FDG corrected for body weight (SUV(BW)). RESULTS: Abdominal SUV(BW) was significantly increased on day 1 (p < 0.0001), day 3 (p < 0.0001), and day 6 (p < 0.05) in the doxorubicin-treated group compared to controls. Abdominal SUV(BW) returned to baseline levels on day 10. In the doxorubicin group, the largest weight loss was observed on day 3 (control vs doxorubicin, mean percent of baseline weight: (98.5 ± 3.2% vs 87.9 ± 4.6%, p < 0.0001). Moreover, in the doxorubicin-treated group, villus lengths were decreased by 23-28% on days 1 and 3 in the small intestine (p < 0.05), and jejunal levels of tumour necrosis factor and interleukin-1β were significantly increased on day 3 (p < 0.05). DISCUSSION: Together, these findings indicate that sequential 2-[(18)F]FDG-PET/CT scans can objectively quantify and evaluate the development and resolution of intestinal inflammation over time in a mouse model of doxorubicin-induced mucositis. Frontiers Media S.A. 2022-12-15 /pmc/articles/PMC9798215/ /pubmed/36591502 http://dx.doi.org/10.3389/fonc.2022.1061804 Text en Copyright © 2022 Dalby, Skallerup, Baun, Christensen, Rathe, Palner, Husby and Moeller https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Dalby, Sina Skallerup, Sofie Baun, Christina Christensen, Lene Gaarsmand Rathe, Mathias Palner, Mikael Husby, Steffen Moeller, Jesper Bonnet PET/CT imaging detects intestinal inflammation in a mouse model of doxorubicin-induced mucositis |
title | PET/CT imaging detects intestinal inflammation in a mouse model of doxorubicin-induced mucositis |
title_full | PET/CT imaging detects intestinal inflammation in a mouse model of doxorubicin-induced mucositis |
title_fullStr | PET/CT imaging detects intestinal inflammation in a mouse model of doxorubicin-induced mucositis |
title_full_unstemmed | PET/CT imaging detects intestinal inflammation in a mouse model of doxorubicin-induced mucositis |
title_short | PET/CT imaging detects intestinal inflammation in a mouse model of doxorubicin-induced mucositis |
title_sort | pet/ct imaging detects intestinal inflammation in a mouse model of doxorubicin-induced mucositis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798215/ https://www.ncbi.nlm.nih.gov/pubmed/36591502 http://dx.doi.org/10.3389/fonc.2022.1061804 |
work_keys_str_mv | AT dalbysina petctimagingdetectsintestinalinflammationinamousemodelofdoxorubicininducedmucositis AT skallerupsofie petctimagingdetectsintestinalinflammationinamousemodelofdoxorubicininducedmucositis AT baunchristina petctimagingdetectsintestinalinflammationinamousemodelofdoxorubicininducedmucositis AT christensenlenegaarsmand petctimagingdetectsintestinalinflammationinamousemodelofdoxorubicininducedmucositis AT rathemathias petctimagingdetectsintestinalinflammationinamousemodelofdoxorubicininducedmucositis AT palnermikael petctimagingdetectsintestinalinflammationinamousemodelofdoxorubicininducedmucositis AT husbysteffen petctimagingdetectsintestinalinflammationinamousemodelofdoxorubicininducedmucositis AT moellerjesperbonnet petctimagingdetectsintestinalinflammationinamousemodelofdoxorubicininducedmucositis |